LifeMD (LFMD) Stock Forecast & Price Target

LifeMD is viewed favorably because its direct-to-patient telehealth model reduces customer acquisition costs and expands access through a nationwide pharmacy network, a fully integrated care center, and AI-enabled operations. The exclusive AT&T collaboration could funnel more than 29 million eligible customers initially, with over 100 million nationwide eligible, and management expects a meaningful topline contribution starting in 4Q26 as the partnership scales. Growth is also supported by strong execution in weight management, where active subscribers reached approximately 356,000 in 2Q26, and by women’s health and XYOSTED, which could add revenue and EBITDA in 2027.

LifeMD is facing a negative fundamental setup because 2Q26 revenue of $47.3M fell 4% YoY and missed expectations, while adjusted EBITDA of ($3.5M) undershot guidance as higher costs from the transition to branded GLP-1s, a new pharma collaboration, and scaling operations pressured margins. Management also lowered FY2026 revenue guidance to $205.5M-$212.5M from $220M-$230M and adjusted EBITDA to ($6M)-break-even, signaling that the profitability benefits from its new pricing and product mix are taking longer than expected. Although active subscribers reached about 356,000 and weight management subscribers rose to about 108,000, only about 8,000 new weight loss members were added in 2Q26 amid intensifying competition and pricing pressure, limiting confidence in near-term growth.